Literature DB >> 9369331

Melatonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress.

L Iacovitti1, N D Stull, K Johnston.   

Abstract

Dopamine (DA) neurons are uniquely vulnerable to damage and disease. Their loss in humans is associated with diseases of the aged, most notably, Parkinson's Disease (PD). There is now a great deal of evidence to suggest that the destruction of DA neurons in PD involves the accumulation of harmful oxygen free radicals. Since the antioxidant hormone, melatonin, is one of the most potent endogenous scavengers of these toxic radicals, we tested its ability to rescue DA neurons from damage/death in several laboratory models associated with oxidative stress. In the first model, cells were grown in low density on serum-free media. Under these conditions, nearly all cells died, presumably due to the lack of essential growth factors. Treatment with 250 microM melatonin rescued nearly all dying cells (100% tau+ neurons), including tyrosine hydroxylase immunopositive DA neurons, for at least 7 days following growth factor deprivation. This effect was dose and time dependent and was mimicked by other antioxidants such as 2-iodomelatonin and vitamin E. Similarly, in the second model of oxidative stress, 250 microM melatonn produced a near total recovery from the usual 50% loss of DA neurons caused by neurotoxic injury from 2.5 microM 1-methyl-4-phenylpyridine (MPP+). These results indicate that melatonin possesses the remarkable ability to rescue DA neurons from cell death in several experimental paradigms associated with oxidative stress.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369331     DOI: 10.1016/s0006-8993(97)00668-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.

Authors:  C C Chiueh; T Andoh; A R Lai; E Lai; G Krishna
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Melatonin and Parkinson's disease.

Authors:  Juan C Mayo; Rosa M Sainz; Dun-Xian Tan; Isaac Antolín; Carmen Rodríguez; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 3.  Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?

Authors:  Naveen Kumar Singhal; Garima Srivastava; Sonal Agrawal; Swatantra Kumar Jain; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2011-12-24       Impact factor: 5.590

4.  Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.

Authors:  C J van der Schyf; K Castagnoli; S Palmer; L Hazelwood; N Castagnoli
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

Review 5.  Physiological and metabolic functions of melatonin.

Authors:  J Barrenetxe; P Delagrange; J A Martínez
Journal:  J Physiol Biochem       Date:  2004-03       Impact factor: 4.158

6.  Antioxidant neuroprotection against ethanol-induced apoptosis in HN2-5 cells.

Authors:  Dhara S Sheth; Nuzhath F Tajuddin; Mary J Druse
Journal:  Brain Res       Date:  2009-06-16       Impact factor: 3.252

Review 7.  The antiapoptotic activity of melatonin in neurodegenerative diseases.

Authors:  Xin Wang
Journal:  CNS Neurosci Ther       Date:  2009-10-10       Impact factor: 5.243

Review 8.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

9.  Antiinflammatory activity of melatonin in central nervous system.

Authors:  Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 10.  Melatonin-based therapeutics for neuroprotection in stroke.

Authors:  Kazutaka Shinozuka; Meaghan Staples; Cesar V Borlongan
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.